"Our current plan is to move into this new market with minimal disruption to our core dental laser business by continuing to perform research, clinical studies, and pursue additional 510(k) applications to further expand WaterLase's capabilities in ophthalmology. At the same time, we are searching for key strategic partners through a joint venture or other similar approach to invest $30 million to $50 million in OCCULASE for a 30 to 50 percent ownership for the purpose of commercializing these opportunities," said Fred Furry, Chief Operating Officer and Chief Financial Officer. "These strategic partners will be investing in OCCULASE, not BIOLASE, and we expect this could serve as an important blueprint for other potential market entries."
Note that BIOL is looking for a partner to invest $30 million to $50 million for a 30% to 50% stake in the Oculase subsidiary. This gives the Oculase subsidiary an initial valuation of $100 million. Also note that BIOL has so few shares outstanding (about 31.28 million share outstanting according to Yahoo) that at a stock price of $4.07 which is Friday's closing price, the market capitalization of the whole of BIOL is a mere $127.31 million. This tells me that BIOL has been grossly undervalued by the market and has a long ways to run as it continues to increase sales and brings on partners to address the new markets for its unique and patent protected laser technology. BIOL may just now be starting to get on the market's radar screen. With proper execution, (and so few shares outstanding) we could see a huge run up in the stock price over the next few years. IMHO